Quote | Appili Therapeutics Inc (OTCMKTS:APLIF)
Last: | $0.0279 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $0.0279 |
High: | $0 |
Low: | $0 |
Volume: | 10 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Appili Therapeutics Inc (OTCMKTS:APLIF)
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) . Appili is a biopharmaceutical company focused on drug develo...
2024-04-02 08:51:10 ET More on Aditx Therapeutics, Appili Therapeutics, etc. Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M Aditxt buys Brain Scientific's portfolio of EEG brain monitoring technologies and devices Financial information ...
Message Board Posts | Appili Therapeutics Inc (OTCMKTS:APLIF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc Company Name:
APLIF Stock Symbol:
OTCMKTS Market:
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and...
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) . Appili is a biopharmaceutical company focused on drug develo...
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX),...